Literature DB >> 12478484

E-cadherin expression in pleomorphic lobular carcinoma: an aid to differentiation from ductal carcinoma.

Amer Wahed1, John Connelly, Tommy Reese.   

Abstract

Pleomorphic lobular carcinoma is a recently described entity separated from classical lobular carcinoma by cytologic pleomorphism. It can have an aggressive clinical course with a higher frequency of recurrence. Histologic differentiation with ductal carcinoma may be difficult, but it is important for this differentiation to be made. E-cadherin is a transmembrane glycoprotein, and complete loss of E-cadherin expression has been observed in invasive lobular carcinoma and lobular carcinoma in situ. Ductal carcinoma retains at least some expression of E-cadherin. We examined the pattern of E-cadherin expression in a series of 14 cases of pleomorphic lobular carcinoma by immunohistochemistry. Twelve of the 14 cases showed no staining (86%); the remaining two cases exhibited 10% to 25% positive cells. In cases with histologic equivocal features, immunohistochemical detection of E-cadherin expression can be a useful diagnostic aid for the differentiation of pleomorphic lobular and ductal carcinoma. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12478484     DOI: 10.1053/adpa.2002.36660

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  12 in total

1.  Expression of E-Cadherin in breast carcinomas and its association with other biological markers - a prospective study.

Authors:  B Rekhi; A Bansal; D Bhatnagar; S Saxena
Journal:  Indian J Surg Oncol       Date:  2010-08-07

2.  Clinicopathologic characteristics of pleomorphic carcinoma of the breast.

Authors:  Jing Zhao; Ronggang Lang; Xiaojing Guo; Ling Chen; Feng Gu; Yu Fan; Xilin Fu; Li Fu
Journal:  Virchows Arch       Date:  2009-12-16       Impact factor: 4.064

Review 3.  Pleomorphic carcinoma of breast: a case report and review of literature.

Authors:  Hongping Tang; Fang Liu; Huang Li; Xinyi Huang; Tong Zhao
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

4.  Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma.

Authors:  Sreeja Sreekumar; Kevin M Levine; Matthew J Sikora; Jian Chen; Nilgun Tasdemir; Dorothy Carter; David J Dabbs; Carolin Meier; Ahmed Basudan; David Boone; Priscilla F McAuliffe; Rachel C Jankowitz; Adrian V Lee; Jennifer M Atkinson; Steffi Oesterreich
Journal:  Endocrinology       Date:  2020-09-01       Impact factor: 4.736

5.  E-Cadherin as a diagnostic biomarker in breast cancer.

Authors:  Rajeev Singhai; Vinayak W Patil; Sanjog R Jaiswal; Shital D Patil; Mukund B Tayade; Amit V Patil
Journal:  N Am J Med Sci       Date:  2011-05

6.  The myoepithelial cell layer may serve as a potential trigger factor for different outcomes of stage-matched invasive lobular and ductal breast cancers.

Authors:  Yi-Hsuan Hsiao; Horng-Der Tsai; Ming-Chih Chou; Yan-gao Man
Journal:  Int J Biol Sci       Date:  2011-02-04       Impact factor: 6.580

7.  Pleomorphic lobular carcinoma in a male breast: a rare occurrence.

Authors:  Bhatia Rohini; P A Singh; Misra Vatsala; Dhingra Vishal; Singhal Mitali; Sharma Nishant
Journal:  Patholog Res Int       Date:  2010-12-01

8.  In situ malignant transformation and progenitor-mediated cell budding: two different pathways for breast ductal and lobular tumor invasion.

Authors:  Yan-Gao Man; Mina Izadjoo; Guohong Song; Alexander Stojadinovic
Journal:  J Cancer       Date:  2011-07-20       Impact factor: 4.207

9.  Aberrant E-cadherin staining patterns in invasive mammary carcinoma.

Authors:  Malini Harigopal; Sandra J Shin; Melissa P Murray; Satish K Tickoo; Edi Brogi; Paul Peter Rosen
Journal:  World J Surg Oncol       Date:  2005-11-14       Impact factor: 2.754

10.  CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.

Authors:  José Roberto F Caldeira; Erika C Prando; Francisco C Quevedo; Francisco A Moraes Neto; Cláudia A Rainho; Silvia R Rogatto
Journal:  BMC Cancer       Date:  2006-03-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.